Layer-by-Layer Based Nanoparticles for Systemic Delivery Applications

Technology #14680

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Inventors
Professor Paula Hammond
Department Chemical Engineering, MIT
External Link (hammondlab.mit.edu)
Zhiyong Poon
Department Chemical Engineering, MIT
Managed By
Jon Gilbert
MIT Technology Licensing Officer
Patent Protection

Stable layer-by-layer coated particles

US Patent Pending 2014-0093575
Publications
Controlling in Vivo Stability and Biodistribution in Electrostatically Assembled Nanoparticles for Systemic Delivery
American Chemical Society, May, 2011

Applications

This invention offers improved Layer-by-Layer film architecture for better film stability and biodistribution of nanoparticles for drug delivery.

Problem Addressed

Layer-by-Layer (LbL) based nanoparticles are promising new systems for use as drug delivery vehicles as many therapeutics and biologically relevant materials can be easily introduced into LbL films noncovalently and under physiological conditions, without significant alteration of their biological properties. Furthermore, LbL films offer spatial, temporal or active control over the release of therapeutics from the surfaces of macroscopic objects and have great versatility since their composition, surface chemistry and dimensions may be manipulated.  However, LbL based nanoparticles have not been demonstrated for systemic delivery in vivo due to challenges in film stability and biodistribution. This invention has generated systemically deliverable LbL nanoparticles for cancer applications.

Technology

In this technology, biodegradable and biocompatible films were constructed using gold nanoparticle and quantum dot core templates and accumulation was measured in mice livers. It was discovered that the stability of nanofilms increases with more bilayers since LbL films are held together by ionic interactions between interpenetrated LbL layers. It was also observed that the terminal layer of the LbL nanoparticles plays a vital role in the biodistribution of the LbL particles and affects non-specific uptake. Hyaluronic acid outer layers, provide a long circulation half-life and much lower accumulation in the liver and kidney. This outer layer proves the viability of this system for cancer delivery as the circulation times of LbL nanoparticles were extended to levels sufficient for passive targeting to solid tumors via EPR.

Advantages

  • Improved film stability allowing for improved biodistribution
  • Systemic delivery of a variety of different therapeutics or biologically relevant materials under physiological conditions
  • Different film architectures allows for tailored circulation half-life and biodistribution for more effective treatments